×
About 398,018 results

Study finds higher risk of skin cancer after childhood organ transplant
https://www.mdedge.com/dermatology/article/255839/nonmelanoma-skin-cancer/study-finds-higher-risk-skin-cancer-after
Christine Kilgore

Jun 28th, 2022 - A large study showing an increased risk of keratinocyte carcinoma (KC) in children who receive a solid-organ transplant highlights the need for early education about risk reduction and more research to determine optimal timing for screening, say an investigator and two dermatologists with expertise in transplant-related skin issues. The increased incidence of KC in pediatric transplant recipien.

Good chemo vs. bad chemo: When too much is a bad thing
https://www.mdedge.com/hematology-oncology/article/255824/renal-cell-carcinoma/good-chemo-vs-bad-chemo-when-too-much-bad
Randy Dotinga

Jun 28th, 2022 - A new study finds that mortality is significantly higher among patients with advanced solid tumors who are admitted to the hospital for chemotherapy treatment. The findings – released in a poster session at the annual meeting of the American Society of Clinical Oncology – found that patients with solid tumors were more likely to be treated for nonurgent indications, not be referred to palliativ.

Racial/ethnic disparities exacerbated maternal death rise during 2020 pandemic.
https://www.mdedge.com/obgyn/article/255812/covid-19-updates/racial/ethnic-disparities-exacerbated-maternal-death-rise
Diana Swift

Jun 28th, 2022 - U. S.

Abortion pills over the counter? Experts see major hurdles in widening U.S. access
https://www.mdedge.com/obgyn/article/255808/business-medicine/abortion-pills-over-counter-experts-see-major-hurdles
Ahmed Aboulenein

Jun 28th, 2022 - WASHINGTON (Reuters) – A pill used to terminate early pregnancies is unlikely to become available without a prescription for years, if ever, experts told Reuters, as the conservative-leaning U. S.

My picks for best of ASCO 2022
https://www.mdedge.com/hematology-oncology/article/255805/asco-lung-cancer/my-picks-best-asco-2022
David H. Henry, MD

Jun 28th, 2022 - CHICAGO – The American Society of Clinical Oncology recently wrapped its annual meeting in Chicago. Many of us attended virtually, or in person, and were wowed by some of the abstracts and their implications for our patients – some practice changing.

Melanoma incidence is up, but death rates are down
https://www.mdedge.com/hematology-oncology/article/255799/melanoma/melanoma-incidence-death-rates-are-down
Jim Kling

Jun 28th, 2022 - CHICAGO – Mortality rates from melanoma have fallen in recent years, likely due to the introduction of checkpoint inhibitors, according to a new analysis of the National Cancer Institute SEER database between 1975 and 2019. “This is very encouraging data and represents the real-world effectiveness of these therapies.

Highlights in Early-Stage Non–Small Cell Lung Cancer From ASCO 2022
https://www.mdedge.com/hematology-oncology/article/255791/asco-lung-cancer/highlights-early-stage-non-small-cell-lung
Howard (Jack) West, MD

Jun 28th, 2022 - Highlights in early-stage non–small lung cancer (NSCLC) from the 2022 American Society of Clinical Oncology Annual Meeting are discussed by Dr Jack West of City of Hope Comprehensive Cancer Center in Duarte, California. He opens with a post hoc analysis of CheckMate 816, which showed that achieving a pathologic complete response with adjuvant nivolumab plus chemotherapy was highly associated wi.

Highlights in Early-Stage Non–Small Cell Lung Cancer From ASCO 2022
https://www.mdedge.com/hematology-oncology/article/255791/conference-recap/highlights-early-stage-non-small-cell-lung
Howard (Jack) West, MD

Jun 28th, 2022 - Highlights in early-stage non–small lung cancer (NSCLC) from the 2022 American Society of Clinical Oncology Annual Meeting are discussed by Dr Jack West of City of Hope Comprehensive Cancer Center in Duarte, California. He opens with a post hoc analysis of CheckMate 816, which showed that achieving a pathologic complete response with adjuvant nivolumab plus chemotherapy was highly associated wi.

Establishing a formalized mentorship program in a community practice
https://www.mdedge.com/gihepnews/article/255776/practice-management/establishing-formalized-mentorship-program-community
Marc Sonenshine, MD

Jun 27th, 2022 - Most GI physicians will tell you that we didn’t get where we are without help along the way. Each of us can point to one – or in most cases, several – specific mentors who provided invaluable guidance when we were in medical school, fellowship, and starting our careers.

FDA approves liso-cel as second-line therapy for LBCL
https://www.mdedge.com/hematology-oncology/article/255765/b-cell-lymphoma/fda-approves-liso-cel-second-line-therapy-lbcl
Sharon Worcester

Jun 27th, 2022 - Lisocabtagene maraleucel, also known as liso-cel (Breyanzi), has been approved by the Food and Drug Administration for the second-line treatment of adult patients with relapsed or refractory large B-cell lymphoma (r/r LBCL). This expanded indication is based on findings from the pivotal phase 3 TRANSFORM study, which showed significant and clinically meaningful improvements with CD19-directed c.

Use of Statins for Primary Prevention Tied to Lower Risk of Hospitalization for COVID-19
https://www.medscape.com/viewarticle/976151

Jun 27th, 2022 - NEW YORK (Reuters Health) - Patients taking statins for primary prevention of cardiovascular disease may have a lower risk of hospitalization for COVID-19 than matched individuals not taking the medications, a large new study suggests. An analysis of data from more than 2 million statin users and a similar number of matched controls revealed a 16% lower risk of hospitalization for COVID-19 amon...

ASCO 2022: Data for Better Decision-Making in the Treatment of Advanced Bladder Cancer
https://www.medscape.com/viewarticle/976182

Jun 27th, 2022 - Tracy L. Rose, MD, MPH, shares the immediate and direct impact of the long-term follow-up data from the JAVELIN Bladder 100 trial, an avelumab maintenance study in patients with advanced urothelial carcinoma, which was part of a poster session at the 2022 ASCO annual meeting. The results of the 38-month follow-up data showed prolonged overall survival in patients using first-line avelumab maint...

Another Public Health Crisis Originating From Gun Violence
https://www.medscape.com/viewarticle/976178

Jun 27th, 2022 - The number of mass shootings in the US has jumped from 272 annually in 2014 to 692 annually in 2021. As these attacks have increased in frequency, averaging more than once daily since 2019, we've slowly become accustomed to their occurrence. Now, guns only reenter the national conversation when there is a particularly devastating event. Most recently, a shooting in an elementary school in Uvald...

Perioperative Hyperglycemia Risky for Nondiabetics
https://www.medscape.com/viewarticle/976189

Jun 27th, 2022 - NEW YORK (Reuters Health) - The complication risk conferred by perioperative hyperglycemia is higher for patients without diabetes than it is for diabetics, a cohort study found. The 5,868 patients - including 969 (17%) with diabetes - underwent either general (83.4%), vascular (2.6%), or gynecologic (14%) surgery with a planned admission at the University of Washington Medical Center. The hosp...

Jury Out on Low-FODMAP Diet for Kids
https://www.medscape.com/viewarticle/976203

Jun 27th, 2022 - There is scarce evidence to support the use of a FODMAP-lowering diet for children with irritable bowel syndrome (IBS), and there is no evidence to recommend its use for other gastrointestinal (GI) diseases and complaints in children, according to a position paper from the European Society for Pediatric Gastroenterology Hepatology and Nutrition (ESPGHAN). A low-FODMAP (fermentable oligosacchari...

Are Pain Meds the Only Option for Chronic Pain in Cirrhosis?
https://www.medscape.com/viewarticle/976207

Jun 27th, 2022 - Pain is common in patients with cirrhosis, and its management presents significant challenges to health care providers, such as worries about GI bleeding, renal injury, falls, and hepatic encephalopathy. To address those issues, researchers at the University of Michigan, Ann Arbor, authored a review, published in Hepatology, that describes the pain syndromes experienced by patients, as well as ...

American Academy of Pediatrics Recommends Adolescent Suicide Screening
https://www.medscape.com/viewarticle/976214

Jun 27th, 2022 - June 24, 2022 — With suicide rates among young people rising in recent years, the American Academy of Pediatrics is now recommending adolescents 12 and up be screened for suicide risk as a part of regular preventive care. The group recently added the recommendation on screening for suicide risk to its depression screening guidelines. Health care providers are urged to ask their young patients a...

Number of US Cancer Survivors Grew to Over 18 Million
https://www.medscape.com/viewarticle/976225

Jun 27th, 2022 - Of more than 18 million Americans who have a history of cancer, two thirds were aged 65 or older as of January 1 of this year, according to a joint report by the American Cancer Society (ACS) and the National Cancer Institute (NCI). This number has increased by more than 1 million since 2019 and will continue to rise. It is predicted that almost 270,000 new cases of prostate cancer will be diag...

Latin American Patients With Diabetes Prefer SGLT2 Inhibitors
https://www.medscape.com/viewarticle/976231

Jun 27th, 2022 - According to findings from a Latin American research team, patients with type 2 diabetes prefer pharmacologic treatment with sodium-glucose cotransporter-2 (SGLT2) inhibitors over treatment with dipeptidyl peptidase-4 (DPP4) inhibitors. The findings of this study were published in Patient Preference and Adherence and highlight the need for clear discussions between patients and physicians befor...

FDA Okays Liso-cel for Second Line in Large B-cell Lymphoma
https://www.medscape.com/viewarticle/976230

Jun 27th, 2022 - Lisocabtagene maraleucel, also known as liso-cel (Breyanzi), has been approved by the Food and Drug Administration for the second-line treatment of adult patients with relapsed or refractory large B-cell lymphoma (r/r LBCL). This expanded indication is based on findings from the pivotal phase 3 TRANSFORM study, which showed significant and clinically meaningful improvements with CD19-directed c...